gw842166
Small moleculeexperimental
Clinical trial activity
6 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2006 (NCT00444769)
Timeline
Indications
Mechanism of action
- Cannabinoid CB2 receptorAGONIST
CNR2 agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NCC1CCOCC1)c1cnc(Nc2ccc(Cl)cc2Cl)nc1C(F)(F)F- Mol. weight
- 449.26 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL225411 ↗
Also known as
- 2-((2,4-dichlorphenyl)amino)-n-((tetrahydro-2h-pyran-4-yl)methyl)-4-(trifluoromethyl)-5-pyrimidinecarboxamide
- gw842166
- gw842166
- gw842166
- gw842166
- gw842166x
- gw842166x
- gw842166x
- gw842166x
- gw 842166x
- gw-842166x
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00554762 | Phase 1 | Nov 1, 2007 | GlaxoSmithKline |
| NCT00536497 | Phase 1 | Sep 1, 2007 | GlaxoSmithKline |
| NCT00479427 | Phase 2 | Jul 1, 2007 | GlaxoSmithKline |
| NCT00511524 | Phase 1 | Jun 1, 2007 | GlaxoSmithKline |
| NCT00447486 | Phase 2 | Apr 1, 2007 | GlaxoSmithKline |
| NCT00444769 | Phase 2 | Oct 1, 2006 | GlaxoSmithKline |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 6 | 6 | 2 | 2006 |
1 organizations
Page 1 / 1